Hypertrophic cardiomyopathy (HCM) is characterized by pathologic hypertrophy in the absence of a potentially causative disease process and carries increased risk of heart failure, atrial fibrillation, and sudden cardiac death. Synergistic use of multi-modal imaging is pivotal and necessary in the diagnosis and management of patients with, or at risk for, HCM. Echocardiography, cardiac MR, and cardiac computed tomography each have important roles and limitations in assessing the morphologic changes responsible for symptoms and morbidity in HCM. In this article, we will explore these modalities and their roles in evaluating HCM.